6200% returns in one year! Multibagger stock hits upper circuit; here's why
The gains in Elitecon International share price today comes after the company announced the board meeting date for fundraising.
The Board of Directors of Elitecon International at its meeting held on Tuesday, July 01, 2025, decided to defer the consideration and approval of raising funds to the next Board meeting which is scheduled to be held on Friday, July 04, 2025.
The company's board of directors on July 4 will discuss and evaluate the proposal for raising funds up to an amount of ₹ 75 crores by way of preferential allotment, issue of convertible warrants, Foreign Currency Convertible Bonds (FCCBs), Qualified Institutional Placement (QIP) or any other permissible instruments, subject to necessary approvals from Shareholders, regulatory bodies and other stakeholders.
In a separate regulatory filing, Elitecon International said that the Statutory Auditors Report on the Annual Audited Financial Results (Standalone & Consolidated) of the Company for the financial year ended March 31, 2025 do not contain any qualifications, reservations or adverse remarks.
'The Statutory Auditors of the Company have issued unmodified opinion/unqualified opinion on the Annual Audited Standalone Financial Results (Standalone & Consolidated) of the Company for the financial year ended March 31, 2025,' Elitecon International said in a stock exchange filing.
Elitecon International share price has rallied 48% in one month, and more than 106% in three months. The stock has jumped 572% on a year-to-date (YTD) basis, and has delivered multibagger returns of 6,200% in one year.
At 10:40 AM, Elitecon International share price was still locked at 5% upper circuit of ₹ 69.67 apiece on the BSE.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
33 minutes ago
- The Hindu
IndiGo appoints Amitabh Kant as non-executive director on board
IndiGo on Thursday announced the appointment of Amitabh Kant as a non-executive director on the Board of Directors of InterGlobe Aviation Limited. Mr. Kant stepped down as India's G20 sherpa and joined Canadian investment firm Fairfax Financial Holdings Ltd as a senior adviser. He was also the Niti Aayog CEO in the past and has held several key positions, including as a director on the board of the National Highways Authority of India (NHAI) and is known to have led infrastructure projects like Delhi-Mumbai Industrial Corridor the expansion of Calicut Airport.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Carlyle Group may sell 10% stake in Piramal Pharma via block deals: Report
United States-based private equity firm Carlyle Group is planning to divest up to 10 per cent stake in Piramal Pharma through block deals, Moneycontrol reported on Thursday, citing sources. The sale could amount to ₹2,600-2,700 crore, the report added. Piramal Pharma sold 20 per cent of its stake to Carlyle Group in June 2020, in a deal worth ₹3,523 crore. According to stock exchange data, it held 18 per cent stake in the pharma firm as of March 31, 2025. Financial services firm Motilal Oswal has been roped in to facilitate the block deals, the report added. Piramal Pharma operates a diverse and global pharmaceutical business, providing a broad range of products and services. It includes Piramal Pharma Solutions (PPS), a fully integrated contract development and manufacturing organisation (CDMO); Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. Piramal Pharma Q4 result In the fourth quarter of FY25, Piramal Pharma posted a consolidated revenue from operations of ₹2,754 crore, marking an 8 per cent increase over the ₹2,552 crore recorded in the same quarter last year. The company's EBITDA (earnings before interest, tax, depreciation, and amortisation) also increased by 8 per cent year-on-year to ₹603 crore, up from ₹556 crore. Profit after tax (before exceptional items) came in at ₹154 crore, reflecting a 16 per cent rise compared to ₹132 crore in the corresponding period of the previous financial year. Shares of Piramal Pharma last traded at ₹202.4 apiece on the BSE at the close of the markets on Thursday.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Brokerages remain cautious on Asian Paints despite recent rally in stock
Shares of Asian Paints rose to a two-month high, but brokerages remain cautious amid regulatory scrutiny and growing competition in the premium segment Deepak Korgaonkar Mum Listen to This Article Shares of the largest Indian paint company, Asian Paints, hit a two-month high of ₹2,464, up 2 per cent on the BSE in Thursday's intra-day trade amid heavy volumes. The stock price of the paint company has bounced back nearly 5 per cent from Wednesday's low, shrugging off the probe by the Competition Commission of India (CCI). The stock, which has outperformed the Nifty50 over the past month by delivering 7.8 per cent returns compared to 3.5 per cent for the benchmark, ended the day a tad higher. The Competition Commission of India (CCI) has ordered its director general (DG)
